What's Happening?
Merck has announced that its combination therapy of KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) has demonstrated significant survival benefits for patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy.
The Phase 3 KEYNOTE-B15 trial revealed that this combination reduced the risk of event-free survival (EFS) events by 47% and the risk of death by 35% compared to neoadjuvant chemotherapy and surgery. The trial's results, presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, highlight the potential of this regimen to become a new standard of care in treating MIBC. The study involved 808 patients and showed that 79.4% of those treated with the combination were alive without disease progression or recurrence at two years, compared to 66.2% for those receiving standard treatment.
Why It's Important?
The findings from the KEYNOTE-B15 trial are significant as they suggest a potential shift in the standard treatment for muscle-invasive bladder cancer, a condition affecting a substantial number of patients worldwide. The combination of KEYTRUDA and Padcev not only improves survival rates but also offers a new therapeutic option for patients who are eligible for cisplatin-based chemotherapy. This development could lead to better patient outcomes and potentially reduce the recurrence rates associated with the current standard of care. The trial's success also underscores the importance of immunotherapy and antibody-drug conjugates in cancer treatment, potentially influencing future research and treatment protocols in oncology.
What's Next?
Following the positive results of the KEYNOTE-B15 trial, Merck, in collaboration with Pfizer and Astellas, plans to share these findings with regulatory authorities globally to seek approval for this combination therapy. If approved, this could lead to broader adoption of the regimen in clinical practice, offering a new standard of care for patients with muscle-invasive bladder cancer. Additionally, ongoing and future trials will continue to explore the efficacy of KEYTRUDA in various stages of bladder cancer, potentially expanding its use and further solidifying its role in cancer treatment.
